The use of calcium carbimide in relapse prevention counseling counselling: Results of a randomized controlled trial. British Journal of Addiction 87:63-72, 1992.
Naltrexone as Adjunctive Treatment to Cognitive Behavioral Therapy for Outpatient Alcoholics. Paper presented at the annual meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 1997.
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry 53(3):225-231, 1996.
Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clinical and Experimental Research 19(3):600-606, 1995.
Pharmacologic interventions for alcohol- and cocaine-abusing individuals: A controlled study of disulfiram vs. naltrexone. American Journal on Addictions 2:77-79, 1993.
Detoxification from Alcohol and Other Drugs. Treatment Improvement Protocol (TIP) Series, Number 19. DHHS Publication No. (SMA) 95-3046. Washington, DC: U.S. Government Printing Office, 1995.
Ethanol increases the expression of functional delta-opioid receptors in the neuroblastoma X glioma NG108-15 hybrid cells. Journal of Biologic Chemistry 261:3164-3169, 1986.
Etiologic factors in substance abuse: An adoption study perspective. In: Pickens, R.W., and Svikis, D.S., eds. Biological Vulnerability to Drug Abuse. NIDA Research Monograph Series, Number 89. Rockville, MD: National Institute on Drug Abuse, 1988. pp. 52-72.
American and European clinical trials of naltrexone. In: Litten, R.Z., and Fertig, J. (chairs), International Update: New Findings on Promising Medications. Alcoholism: Clinical and Experimental Research 20(8 suppl.):216A-218A, 1996.
The safety profile of naltrexone in the treatment of alcoholism: Results from a multicenter usage study. Archives of General Psychiatry 54(12):1130-1135, 1997.
A Multicenter Safety Study of Naltrexone as Adjunctive Pharmacotherapy for Individuals with Alcoholism. Paper presented at the American Psychiatric Association's 148th annual meeting in Miami, May 20-25, 1995.
The alcohol-preferring C57-L/6 mice present an enhanced sensitivity of the hypothalmic b-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. Journal of Pharmacology and Experimental Therapeutics 281:788-794, 1992.
Answers to frequently asked questions about naltrexone treatment for alcoholism. In: Rounsaville, B.J.; O'Malley, S.; and O'Conner, P., eds. Guidelines for the Use of Naltrexone in the Treatment of Alcoholism. New Haven, CT: APT Foundation, 1995.
Clinical overview of alcohol and drug disorders. In: Fleming, M.F., and Barry, K.L., eds. Addictive Disorders. Chicago: Mosby Yearbook, 1992. pp. 3-21.
Endorphins in individuals with high and low risk for development of alcoholism. In: Reid, L.D., ed. Opioids, Bulimia, and Alcohol Abuse and Alcoholism. New York: Springer-Verlag, 1990. pp. 229-246.
Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192-213, 1988.
DSM-II-R and proposed DSM-IV alcohol abuse and dependence, United States, 1988: A nosological comparison. Alcoholism: Clinical and Experimental Research 16(6):1068-1077, 1992.
Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states. Annals of the New York Academy of Sciences 281:297-310, 1976.
Naltrexone, relapse prevention, and supportive therapy with alcoholics: An analysis of patient treatment matching. Journal of Consulting and Clinical Psychology 64:1044-1053, 1996.
Narcotic Antagonists: Naltrexone Progress Report. NIDA Research Monograph Series, Number 9. DHEW Publication No. (ADM) 76-387. Bethesda, MD: National Institute on Drug Abuse, 1976.
Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15-22, 1997.
Alcohol: The reward system and dependence. In: Jansson, B.; Jörnvall, H.; Rydberg, U.; Terenius, L.; and Vallee, B.L., eds. Toward a Molecular Basis of Alcohol Use and Abuse, Boston: Birkhauser-Verlag, 1994. pp. 103-114.
Basic Neurobiological Research: 1989-1991. Drug Abuse and Drug Abuse Research: Fourth Triennial Report to Congress from the Secretary, Department of Health and Human Services. Rockville, MD: National Institute on Drug Abuse, 1991 (unpublished document).
Alcohol alters preproenkephal in mRNA content in the shell and the core of the nucleus accumbens. Alcoholism: Clinical and Experimental Research 20:53A, 1996.
Pharmacotherapies for alcohol problems: A review of research with focus on developments since 1991. Alcoholism: Clinical and Experimental Research 20:859-876, 1996.
[Effect of methadone or naltrexone on the course of transaminase[s] in parenteral drug users with hepatitis C virus infection.] Revista Clinica Espanola 197(7):479-483, 1997.
A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association 275:761-767, 1996.
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol: Clinical and Experimental Research 18(5):1162-1167, 1994.
Naltrexone in the Treatment of Alcohol-Dependent, Mentally Ill Patients: A Retrospective Analysis of 83 Cases. Paper presented at the annual meeting of the American Society of Addiction Medicine, San Diego, California, April 1997.
Efficacy of naltrexone for alcoholics with and without comorbid opiate or cocaine dependence. In: Litten, R.Z., and Fertig, J., Chairs. International Update: New Findings on Promising Medications. Alcoholism: Clinical and Experimental Research 20(suppl.):216A-218A, 1996.
Operant analysis of human heroin self-administration and the effects of naltrexone. Journal of Pharmacology and Experimental Therapeutics 216:45-54, 1981.
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology and Therapeutics 47:490-498, 1990.
Eighth Special Report to the U.S. Congress on Alcohol and Health From the Secretary of Health and Human Services, September 1993. NIH Pub. No. 94-3699. Bethesda, MD: National Institutes of Health, 1994.
A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers. American Journal of Medicine 103(6):477B482, 1997.
Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association 279(3):229B234, 1998.
Comorbidity of mental disorders with alcohol and other drug use: Results from the epidemiologic catchment area (ECA) study. Journal of the American Medical Association 264:2511-2518, 1990.
The Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1985. DHHS Publication No. (ADM) 90-1694. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1990.
Alcohol and opiate dependence: Reevaluation of the Victorian perspective. In: Cappell, H.D.; Glaser, F.B.; and Israel, Y., et al., eds. Research Advances in Alcohol and Drug Problems, Volume 9. New York: Plenum Press, 1986. pp. 279-314.
National Household Survey on Drug Abuse Advance Report No. 18. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1996. http://ncadi.samhsa.gov/ [Accessed Nov. 6, 1997].
Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proceedings of the National Academy of Sciences 83:4071-4075, 1986.
Single-dose ethanol administration activates the hypothalamic-pituitary axis: Exploration of the mechanism of action. Neuroendocrinology 50:427-432, 1989.
Quantitative determination of 2-hydroxy-3-methoxy-6 beta-naltrexol (HMN), naltrexone, and 6 beta-naltrexol in human plasma, red blood cells, saliva, and urine by has liquid chromatography. Journal of Analytical Toxicology 4(1):33-37, 1980.
Medical Treatments for Alcohol Dependence. Speech delivered by satellite broadcast to Veterans' Affairs hospitals in the United States and reported by the Treatment Research Center, on November 30, 1995.
Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid drinking behavior and "relapse" in morphine addicted rats. Psychopharmacologia 10:255-284, 1967.
Acamprosate: A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53(6):1038-1053, 1997.
Site Map
Help
Account
Cart
Home
